Similarly, TIM-3 inhibitors combined with demethylation drugs (azacitidine or decitabine) is used as the treatment strategy for AML, and one of the clinical trial adopts the combination of spartalizumab (PD-1 inhibitor) and sabatolimab (NCT03066648), which indicates that TIM3 inhibitors will occupy the market in the field of AML in the future. This evidence concerns the gene PDCD1 and acute myeloid leukemia.